

# HALTING PANCREATIC CANCER IS URGENT

INCREASE FUNDING FOR THE NIH AND NCI TO CONTINUE LIFESAVING RESEARCH



A continued and robust investment in research funding at the National Institutes of Health (NIH) and National Cancer Institute (NCI) is needed to provide pancreatic cancer patients more moments that matter.

## YOU CAN'T IGNORE THESE FACTS

- Pancreatic cancer is one of the deadliest major cancers with the lowest survival rate at just **9 percent**.<sup>1</sup>
- It is the **3rd leading cause of cancer-related death** in the U.S.<sup>1</sup>
- There is **no early detection method**.
- There are **few effective treatment options**.

**“THE FEDERAL FUNDING THAT I’VE RECEIVED IS CRITICAL TO SUSTAIN THE LAB, ALLOW THE RESEARCH TO CONTINUE AND HELP ME FOCUS ON THE SCIENCE.”**

— **Cosimo Commisso, PhD**

Assistant Professor, Sanford Burnham Prebys Medical Discovery Institute

Pancreatic Cancer Researcher

## NIH AND NCI FUNDING IS CRITICAL TO ACCELERATING PANCREATIC CANCER DISCOVERIES

NIH and NCI funding supports the basic science research necessary to devise better early detection strategies and more effective treatments.

NIH funding is critical to the nation’s economy and job creation, contributing to:




nearly **\$74 billion** in economic activity<sup>2</sup>



**433,000 jobs**<sup>2</sup>

More NIH and NCI funding correlates with better survival



Tomorrow’s moments depend on today’s investments in lifesaving cancer research.

**THE PANCREATIC CANCER ACTION NETWORK URGES THE 116TH CONGRESS TO MAKE MORE MOMENTS MATTER:**

Support **\$41.6 billion for the NIH** in FY 2020,  
including **\$6.5 billion for the NCI**.

1. American Cancer Society. Cancer Facts & Figures 2019. Atlanta: American Cancer Society; 2019.  
2. NIH’s Role in Sustaining the U.S. Economy 2019 Update, United for Medical Research (accessed: May 2019).  
3. NCI Funded Research Portfolio – <http://fundedresearch.cancer.gov/nciportfolio/> (accessed: May 2019).  
4. American Cancer Society, Cancer Facts and Figures 1999-2019, SEER-9 database.

Los Angeles Office | 1500 Rosecrans Ave., Ste. 200 | Manhattan Beach, CA 90266  
Washington, D.C. Office | 1050 Connecticut Ave. NW, Ste. 500 | Washington, D.C. 20036  
New York Office | 300 Park Ave. | New York, NY 10022